Gene Therapy in Ophthalmology: The Future of Inherited Retinal Diseases

Mehmona Asgher

Introduction:

Inherited retinal diseases (IRDs) encompass a diverse group of genetic disorders leading to progressive vision loss and in many cases complete blindness. Recent advancements in gene therapy have ushered in promising avenues for treating these conditions, offering hope for vision restoration.

Advancements in Gene Therapy for IRDs

The eye's unique characteristics, such as its accessibility, immune-privileged status and the presence of the blood-retinal barrier make it an ideal candidate for gene therapy interventions. These features facilitate targeted delivery of therapeutic genes while minimizing systemic side effects. One notable success is the development of voretigene neparvovec (Luxturna), an FDA-approved gene therapy for Leber congenital amaurosis caused by RPE65 mutations. This therapy involves delivering a functional copy of the RPE65 gene directly into retinal cells, leading to significant improvements in visual function¹.

Recent Clinical Successes

A groundbreaking clinical application of gene therapy was reported in London, where doctors successfully treated children with Leber Congenital Amaurosis by injecting healthy copies of the AIPL1 gene into their eyes. This intervention enabled the children to perceive shapes, recognize faces and engage in activities like reading and writing, marking a significant milestone in pediatric ophthalmic care².

Challenges and Future Directions

Despite these successes, several challenges persist in the widespread application of

gene therapy for IRDs. The genetic heterogeneity of these diseases necessitates the development of personalized therapies tailored to specific mutations. Additionally, ensuring long-term expression and efficacy of the introduced genes remains a critical area of research. Ongoing studies are exploring advanced delivery vectors and genome editing techniques to enhance the precision and durability of gene therapies³. In conclusion, gene therapy stands at the forefront of innovative treatments for inherited retinal diseases, transforming once incurable conditions into manageable ones with the potential for vision restoration. Continued research and clinical trials are essential to overcome existing challenges and expand the applicability of these therapies to a broader spectrum of retinal disorders.

References:

- 1. Leber congenital amaurosis. In: Wikipedia. Available from: <u>https://en.wikipedia.org/wiki/Congenital_blindness</u>
- 2. Doctors in London cure blindness in children with rare condition. In: The Guardian. Available from: <u>https://www.theguardian.com/so</u> <u>ciety/2025/feb/20/doctors-in-london-</u> <u>cure-blindness-in-children-with-rarecondition</u>
- 3. Gene therapy for inherited retinal diseases: exploiting new tools in preclinical and clinical research. In: Frontiers in Ophthalmology. Available from: <u>https://www.frontiersin.org/journ als/ophthalmology/articles/10.3389/fop ht.2023.1270561/full</u>